| Title | Venue | Year | Impact | Source |
| 4051 | FACTORS ASSOCIATED WITH WEIGHT GAIN DURING THE COVID-19 PANDEMIC | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4052 | PATIENTS WITH POST-COVID-19 VACCINATION MYOCARDITIS HAVE GREATER STRAIN THAN THOSE WITH NON-VACCINE MYOCARDITIS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4053 | TIME SINCE LAST CHEMOTHERAPY AND COVID-19 OUTCOMES IN CARDIO-ONCOLOGY INPATIENTS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4054 | HEALTH DISPARITIES INVOLVING HOSPITALIZATIONS AMONG COVID-19 VACCINATED CARDIOVASCULAR DISEASE PATIENTS INFECTED BY SARS-COV-2 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4055 | CLINICAL AND ECONOMIC OUTCOMES OF PHARMACOLOGICAL STRESS TESTS IN PATIENTS WITH A HISTORY OF COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4056 | SYSTEMATIC REVIEW AND META-ANALYSIS OF REMDESIVIR AND BRADYCARDIA IN PATIENTS WITH COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4057 | IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON SHORT-TERM OUTCOME IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION DURING COVID-19 PANDEMIC: INSIGHTS FROM THE INTERNATIONAL MULTICENTER ISACS-STEMI REGISTRY | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4058 | CONTROL OF ATHEROSCLEROTIC RISK FACTORS BEFORE AND DURING THE COVID-19 PANDEMIC | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4059 | ORAL ANTICOAGULATION IN HOSPITALIZED PATIENTS WITH COVID-19, IS IT BENEFICIAL OR HARMFUL ? | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4060 | AGE-RELATED EFFECTS OF COVID-19 PANDEMIC ON MECHANICAL REPERFUSION AND 30-DAY MORTALITY FOR STEMI: RESULTS OF THE ISACS-STEMI COVID-19 REGISTRY | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4061 | CARBOPLATIN-PACLITAXEL INDUCED ACUTE MULTI-VESSEL CORONARY THROMBOSIS Background: Delayed cancer screenings during COVID-19 pandemic are expected to increase use of chemotherapy agents like paclitaxel. Paclitaxel has been implicated in rare cases of acute myocardial infarction from chemotoxicity. We present a rare case and literature review of Paclitaxel-induced acute multiple vessel coronary thrombosis in absence of native coronary artery atherosclerosis. Case: A 68-year-old man with a history of metastatic stage IV non-small cell lung cancer, hypertension, hyperlipidemia, normal baseline left ventricular systolic function and without coronary disease on recent heart catheterization, was found unresponsive with telemetry showing monomorphic ventricular tachycardia six hours post Carboplatin-Paclitaxel infusion. Decision-making: The patient was emergently cardioverted at bedside, intubated, and started on amiodarone, lidocaine, and norepinephrine infusions. The patient was thrombocytopenic at 61K, leukopenic at 1.2K, and anemic at 7.1 with INR of 1.8. ECG showed new ST-elevation in inferior leads. Bedside echocardiogram revealed global hypokinesis with apical akinesis and a newly reduced LVEF 25%. Troponin measured 0.5 ng/mL (normal <0.04 ng/mL), creatinine 1.4, K+ 3.4, and Mg2+ 1.8. After cardio-oncology led multidisciplinary discussion, a decision was made to pursue invasive angiogram. Found to have de novo triple-vessel coronary thrombosis in mid-LAD, proximal OM1 and mid RCA (Figure 2), percutaneous intervention was performed with drug-eluting stents placed in mid-LAD and mid-RCA, with staged PCI planned on proximal OM1 if needed. Patient responded well to the intervention and was extubated the same day. Patient remained medically stable at 3-month follow-up despite continued chemotherapy. Staged PCI to OM1 was not needed. Conclusion: Paclitaxel based therapy can cause ventricular arrhythmias and sudden cardiac death secondary to acute multi-vessel coronary thrombosis in patients without underlying coronary artery disease in the setting of pronounced thrombocytopenia. Prompt recognition of this severe adverse effect and timely utilization of multidisciplinary care models led by a cardio-oncologist achieves optimal outcomes. | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4062 | STEPWISE SCREENING OF PATIENTS REFERRED TO A COVID-19 CARDIOLOGY CLINIC FOR PERSISTENT CARDIOVASCULAR SYMPTOMS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4063 | LEFT MAIN ARTERY PSEUDOANEURYSM IN A PATIENT WITH SARS-COV-2 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4064 | GENDER BASED DIFFERENCES IN CARDIOVASCULAR OUTCOMES ASSOCIATED WITH COVID-19 INFECTION: A SYSTEMIC REVIEW AND META-ANALYSIS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4065 | COMPARISONS OF THE PRONE-POSITION AND THE STANDARD 12-LEADS ELECTROCARDIOGRAM: A PROSPECTIVE STUDY IN COVID-19 PATIENTS WITH PULMONARY INVOLVEMENT | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4066 | COVID-19 M-RNA VACCINE ASSOCIATED MYOCARDITIS: A REPORT ON SHORT TERM FOLLOW UP CARDIAC IMAGING AND CLINICAL OUTCOMES | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4067 | LOW-DOSE ASPIRIN AND MORTALITY IN PATIENTS WITH COVID-19: A META-ANALYSIS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4068 | CRITICALLY ILL COVID-19 PATIENTS AND THERAPEUTIC ANTICOAGULATION WITH HEPARIN | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4069 | PSYCHOSOCIAL FACTORS AMONG A SAMPLE OF CARDIAC REHABILITATION PATIENTS THAT HAVE GONE THROUGH COVID-19 INFECTION | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4070 | IMPACT OF CARDIOVASCULAR RISK FACTOR CONTROL AND Healthcare RESOURCE UTILIZATION DURING THE COVID-19 PANDEMIC | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4071 | THE CLINICAL COURSE OF PATIENTS WITH A HISTORY OF ACUTE PERICARDITIS FOLLOWING VACCINATION AGAINST SARS-COV2 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4072 | LONG TERM CMR CHARACTERIZATION OF ATHLETES RECOVERING FROM COVID-19 INFECTION AND RETURN TO PLAY | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4073 | RACIAL AND ETHNIC DISPARITIES IN DELAYING OR NOT RECEIVING MEDICAL CARE DURING THE COVID-19 PANDEMIC IN THE UNITED STATES | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4074 | THE EFFECT OF TREATMENT WITH HYDROXYCHLOROQUINE AND AZITHROMYCIN ON THE CORRECTED QT INTERVAL IN PATIENTS WITH COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4075 | DIFFERENTIAL MORTALITY AMONG HEART FAILURE PATIENTS DURING FIRST AND SECOND COVID-19 SURGES IN NEW YORK | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4076 | EFFECT OF TOCILIZUMAB ON NEW ONSET ATRIAL FIBRILLATION AND MORTALITY IN COVID-19 PATIENTS: AN UMBRELLA REVIEW | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4077 | THE IMPACT OF ORAL ANTICOAGULANTS ON THE OUTCOMES OF COVID-19 PATIENTS WITH A HISTORY OF HF AND ATRIAL FIBRILLATION | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4078 | SUSTAINED IMPACT OF THE COVID-19 PANDEMIC ON PRESENTATIONS WITH ST-SEGMENTELEVATION MYOCARDIAL INFARCTION | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4079 | H2C2 (HOME HOSPITAL AND CRITICAL CARE)-A 2.5 YEAR EXPERIENCE USING A NEW MODEL OF HOSPITAL AT HOME: DEVELOPMENT AND IMPLEMENTATION Background: The CMS Hospital at Home (H@H) program during the COVID 19 pandemic was successfully applied as a suitable alternative to unnecessary admissions in lower risk patient populations. As the top 5% pts ($50,000/Year) account for 50% of the US healthcare expenditure over 15 years (5:50 Rule), we sought to investigate the long-term clinical and financial effectiveness and sustainability of new model of home hospital and critical care (H2C2) on the top 5% patients. Methods: 68 consecutive pts with top 5% annual cost profile (~4 admissions/pt with severe chronic dx [CHF, CAD, CODP, sepsis] +/-ventilator, PEG, dialysis, LifeVest) were enrolled in a multiple MSO program. On-site & On-line care started 3/2019 via patented processes and individualized protocols/devices (24/7 monitoring + ICU level Telemetry, 12-lead ECG). All Medicare Part A, B & D costs, admissions and LOS for pts were computed and normalized per phase (PRIOR, DURING, POST H2C2) to determine effectiveness and sustainability. Results: Of the 68 patients, 90% discharged to PCP, 6% admitted to hospice and 4% remained on the program for continuous care. There were no deaths at home. Compared to baseline, H2C2 had an over 70% sustained total cost reduction. Conclusion: This is 1st study to assess long-term clinical & financial impacts of H2C2 in top 5% of high-risk/cost pts. H2C2 was safe with a significantly sustained reduction of admissions and costs both during and 1.5 years post H2C2. Further studies are warranted for scalability. [Formula presented] | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4080 | A SYSTEMATIC REVIEW ON ECHOCARDIOGRAPHIC FINDINGS OF MYOCARDITIS AFTER THE SECOND COVID-19 MRNA VACCINATION DOSE | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4081 | CARDIOVASCULAR PATIENT OUTCOMES AND COMPLICATIONS AFTER SARS-COV-2 INFECTION | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4082 | PERICARDIAL INVOLVEMENT IN HOSPITALIZED PATIENTS WITH COVID-19- PREVALENCE, ASSOCIATES AND CLINICAL IMPLICATIONS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4083 | CLINICAL CHARACTERISTICS OF NEUROLOGICAL DISEASE AND COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4084 | MALE SEX, HLA-C*04:01 AND COVID-19: A RISKY CONSTELLATION | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4085 | CARDIORESPIRATORY INDICES IN RELATION TO MARKERS OF PSYCHOPATHOLOGY AND NEUROCOGNITIVE FUNCTION IN POST SARS-COV-2 INFECTED SUBJECTS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4086 | SURVIVAL OUTCOMES OF PEDIATRIC PATIENTS WITH COVID-19 INFECTION AND IN-HOSPITAL CARDIOPULMONARY RESUSCITATION | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4087 | INCIDENCE AND OUTCOMES OF IN-HOSPITAL CARDIAC ARREST DURING THE COVID-19 PANDEMIC AND THE PRECEDING ERA: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4088 | ASSOCIATION OF LIPID LEVELS WITH COVID-19 INFECTION, DISEASE SEVERITY AND MORTALITY | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4089 | THE INCIDENCE OF CARDIAC ARRHYTHMIAS IN PATIENTS WITH COVID-19: A META-ANALYSIS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4090 | PERSONALIZING THE OPTIMAL CARDIAC TROPONIN THRESHOLD FOR COVID-19 PROGNOSTICATION BASED ON PRE-EXISTING COMORBIDITIES | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4091 | FORMER INCARCERATION AS A RISK FACTOR FOR COVID-19 ASSOCIATED SUDDEN DEATH | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4092 | ASSOCIATION OF BLOOD VISCOSITY AND PROGNOSIS OF HOSPITALIZED COVID-19 PATIENTS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4093 | URIC ACID TO HIGH DENSITY LIPOPROTEIN CHOLESTEROL RATIO IS A SIGNIFICANT PREDICTOR OF MORTALITY IN PATIENTS HOSPITALIZED WITH COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4094 | RELATIONSHIP BETWEEN ADMISSION TROPONIN AND OUTCOMES IN CRITICALLY ILL PATIENTS WITH HEART DISEASE AND COVID-19 IN A TERTIARY CENTER IN BRAZIL | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4095 | WHOSE DOSE IS IT ANYWAY? INDIVIDUAL PATIENT DOSE-RESPONSE CURVES FROM THE REMOTE-CARE PERSONAL-COVIDBP TRIAL | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4096 | CARDIOVASCULAR COMPLICATIONS OF COVID-19 AND IT'S TRUE MORTALITY IN A LARGE METROPOLITAN HEALTH SYSTEM | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4097 | CARDIAC MANIFESTATIONS OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN AT A TERTIARY REFERRAL CHILDREN'S HOSPITAL Background: Since the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a new multisystem inflammatory syndrome in children (MIS-C) has been described amongst patients with recent past SARS-CoV-2 infection. The primary objective of this study is to describe a single center experience in relation to cardiac manifestations of MIS-C in an ethnically diverse pediatric population. Methods: We conducted a retrospective chart review of pediatric patients less than 21 of age meeting MIS-C criteria who presented to a tertiary care children's hospital from May 2020 to March 2021. Results: Seventy-eight patients diagnosed with MIS-C (average age 9.7 +/- 4.6 years, 57% male) were included in this study (60 Hispanic, 9 non-Hispanic White, 7 Black, and 1 American Indian). The most common presenting symptoms were nausea and vomiting (76%), abdominal pain (71%), appetite changes (69%), fatigue (64%), and conjunctivitis (63%). The average length of intensive care unit stay was 2.5 days while average total hospitalization was 7.3 days. Forty-nine patients (62%) underwent echocardiography. Of those evaluated, there was systolic dysfunction in 45% with an average ejection fraction of 48%, diastolic dysfunction in 14%, valvular disease in 53%, coronary involvement in 16%, and pericardial effusion in 22%. Electrocardiogram was completed on 37 patients (47%) which revealed heart block in 23% and arrhythmia in 3%. Troponin T was elevated in 32% and pro-BNP was elevated in 89%. Ninety-five percent of patients received immunomodulators during their hospitalization, while 94% received methylprednisolone, 59% received intravenous immunoglobulin, and 19% received Anakinra. There was one mortality. Conclusion: The results of this retrospective study contribute to a growing knowledge base in the literature that MIS-C can exhibit a wide spectrum of cardiac manifestations further underscoring the importance of thorough cardiac workup and regular outpatient follow-up in patients diagnosed with MIS-C. | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4098 | BODY MASS INDEX AS A PREDICTOR OF MORTALITY IN PATIENTS ADMITTED WITH COVID-19, A RETROSPECTIVE STUDY | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4099 | COVID-19 COMPLICATED BY HIGH-GRADE ATRIOVENTRICULAR BLOCK | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4100 | HYBRID MANAGEMENT OF HEART FAILURE DURING THE COVID-19 PANDEMIC AFTER ADOPTION OF A TELEHEALTH MODEL | J Am Coll Cardiol | 2022 | | CORD-19 |
